Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

192,640 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Single-cell transcriptomic profiling reveals the tumor heterogeneity of small-cell lung cancer.
Tian Y, Li Q, Yang Z, Zhang S, Xu J, Wang Z, Bai H, Duan J, Zheng B, Li W, Cui Y, Wang X, Wan R, Fei K, Zhong J, Gao S, He J, Gay CM, Zhang J, Wang J, Tang F. Tian Y, et al. Among authors: wang x, wang z, wang j. Signal Transduct Target Ther. 2022 Oct 5;7(1):346. doi: 10.1038/s41392-022-01150-4. Signal Transduct Target Ther. 2022. PMID: 36195615 Free PMC article.
TCR Repertoire Diversity of Peripheral PD-1+CD8+ T Cells Predicts Clinical Outcomes after Immunotherapy in Patients with Non-Small Cell Lung Cancer.
Han J, Duan J, Bai H, Wang Y, Wan R, Wang X, Chen S, Tian Y, Wang D, Fei K, Yao Z, Wang S, Lu Z, Wang Z, Wang J. Han J, et al. Among authors: wang x, wang z, wang j, wang y, wang d, wang s. Cancer Immunol Res. 2020 Jan;8(1):146-154. doi: 10.1158/2326-6066.CIR-19-0398. Epub 2019 Nov 12. Cancer Immunol Res. 2020. PMID: 31719056
Allele Frequency-Adjusted Blood-Based Tumor Mutational Burden as a Predictor of Overall Survival for Patients With NSCLC Treated With PD-(L)1 Inhibitors.
Wang Z, Duan J, Wang G, Zhao J, Xu J, Han J, Zhao Z, Zhao J, Zhu B, Zhuo M, Sun J, Bai H, Wan R, Wang X, Fei K, Wang S, Zhao X, Zhang Y, Huang M, Huang D, Qi C, Gao C, Bai Y, Dong H, Xiong L, Tian Y, Wang D, Xu C, Wang W, Li J, Hu X, Cai S, Wang J. Wang Z, et al. Among authors: wang x, wang g, wang w, wang j, wang d, wang s. J Thorac Oncol. 2020 Apr;15(4):556-567. doi: 10.1016/j.jtho.2019.12.001. Epub 2019 Dec 12. J Thorac Oncol. 2020. PMID: 31843683 Free article.
EPHA mutation as a predictor of immunotherapeutic efficacy in lung adenocarcinoma.
Bai H, Duan J, Li C, Xie W, Fang W, Xu Y, Wang G, Wan R, Sun J, Xu J, Wang X, Fei K, Zhao Z, Cai S, Zhang L, Wang J, Wang Z. Bai H, et al. Among authors: wang x, wang g, wang j, wang z. J Immunother Cancer. 2020 Dec;8(2):e001315. doi: 10.1136/jitc-2020-001315. J Immunother Cancer. 2020. PMID: 33303576 Free PMC article.
Biomarker subset analysis of a phase IIIb, open-label study of afatinib in EGFR tyrosine kinase inhibitor-naive patients with EGFRm+ non-small-cell lung cancer.
Zhao J, Bai H, Wang X, Wang Y, Duan J, Chen H, Xue Z, Tian Y, Cseh A, Huang DC, Wu YL, Wang J. Zhao J, et al. Among authors: wang x, wang j, wang y. Future Oncol. 2022 Apr;18(12):1485-1497. doi: 10.2217/fon-2021-0394. Epub 2022 Feb 4. Future Oncol. 2022. PMID: 35114807 Free article. Clinical Trial.
192,640 results
You have reached the last available page of results. Please see the User Guide for more information.